作者 Gao, Jialiang; Chen, Guang; He, Haoqiang; Liu, Chao; Xiong, Xingjiang; Li, Jun; Wang, Jie
期刊 FRONTIERS IN PHARMACOLOGY , MAY 23 2017,:8
DOI 10.3389/fphar.2017.00289 PubMed 28588491
摘要 Breviscapine is a crude extract of several flavonoids of Erigeron breviscapus (Vant.) Hand.-Mazz., containing more than 85% of scutellarin, which has been traditionally used in China as an activating blood circulation medicine to improve cerebral blood supply. Accumulating evidence from various in vivo and in vitro studies has shown that breviscapine exerts a broad range of cardiovascular pharmacological effects, including vasodilation, protection against ischaemia/reperfusion (I/R), anti-inflammation, anticoagulation, antithrombosis, endothelial protection, myocardial protection, reduction of smooth muscle cell migration and proliferation, anticardiac remodeling, antiarrhythmia, blood lipid reduction, and improvement of erectile dysfunction. In addition, several clinical studies have reported that breviscapine could be used in conjunction with Western medicine for cardiovascular diseases (CVDs) including coronary heart disease, myocardial infarction, hypertension, atrial fibrillation, hyperlipidaemia, viral myocarditis, chronic heart failure, and pulmonary heart disease. However, the protective effects of breviscapine on CVDs based on experimental studies along with its underlying mechanisms have not been reviewed systematically. This paper reviewed the underlying pharmacological mechanisms in the cardioprotective effects of breviscapine and elucidated its clinical applications.
版权所有 Copyright © 2002-2025 中国科学院昆明植物研究所,All Rights Reserved 【滇ICP备05000394号】
地址:中国云南省昆明市蓝黑路132号 邮政编码:650201 点击这里联系我们